Optimizing Pulmonology AIM Specialty Health Integration for Accelerated Approvals

Klivira's advanced platform streamlines the complex workflow of **pulmonology AIM Specialty Health integration**, accelerating prior authorization approvals for critical respiratory therapies and diagnostics.

Managing prior authorizations for pulmonology services presents unique challenges, particularly with high-cost biologics, durable medical equipment, and advanced diagnostics. When a specialty benefit manager like AIM Specialty Health is involved, the process adds another layer of complexity, demanding precise documentation and adherence to specific clinical criteria. Klivira provides a robust solution to automate these workflows, reducing administrative burden and improving patient access to care.

The Evolving Landscape of Pulmonology Prior Authorizations

Pulmonology practices frequently encounter prior authorization requirements for a range of critical services. This includes high-cost asthma biologics such as omalizumab, mepolizumab, dupilumab, and tezepelumab, as well as essential durable medical equipment like home oxygen and BiPAP/CPAP devices. Additionally, advanced diagnostics like pulmonary function testing and therapies for conditions such as idiopathic pulmonary fibrosis often trigger PA.

Navigating AIM Specialty Health Requirements in Pulmonology

AIM Specialty Health, as a specialty benefit manager, plays a crucial role in overseeing the prior authorization process for specific high-cost services and medications on behalf of various health plans. While their scope often includes radiology, sleep, cardiology, and musculoskeletal services, their involvement in pulmonology typically focuses on ensuring medical necessity for advanced therapies and diagnostics. Effective integration with AIM's review processes is essential for timely approvals.

Common Pulmonology Services Subject to AIM Specialty Health Review

Asthma biologics (e.g., Dupixent, Nucala, Fasenra, Tezspire, Xolair)
Home oxygen and BiPAP/CPAP equipment
Pulmonary function testing
Antifibrotic therapies for Idiopathic Pulmonary Fibrosis (e.g., Esbriet, Ofev)
Certain COPD specialty drugs (e.g., Ohtuvayre, specific triple-therapy inhalers)
Lung transplant evaluation and associated immunosuppression

Automating Documentation for Pulmonology Biologics and DME

Klivira's platform is designed to address the specific documentation demands of pulmonology prior authorizations. For asthma biologics, our system automates the collection of critical data points such as eosinophil counts, prior controller therapy at maximum dose, and exacerbation history, aligning with guidelines from bodies like GINA, GOLD, and ATS. This proactive approach helps mitigate common denial reasons, including unmet step-therapy requirements or eosinophil-count thresholds.

Klivira's Integration with Specialty Benefit Managers

Klivira offers robust integration capabilities with various payer channels, including specialty benefit managers like AIM Specialty Health. By leveraging EMR integration points, our platform extracts necessary clinical data, populates authorization requests, and submits them through the appropriate payer portals or electronic prior authorization (ePA) channels. This reduces manual data entry and ensures that all required clinical documentation, from diagnostic results to treatment plans, is accurately transmitted.

Enhancing Workflow Efficiency and Approval Rates

Our solution incorporates GINA/GOLD/ATS-aware step-therapy logic and automates eosinophil-count documentation to streamline the asthma biologic prior authorization and re-authorization workflow. By proactively identifying and addressing common denial factors, Klivira helps pulmonology practices achieve higher approval rates and improve turnaround times, ultimately enhancing patient access to vital treatments and reducing administrative burden on PA coordinators.

Frequently asked questions

What specific pulmonology services commonly require prior authorization through AIM Specialty Health?

For pulmonology, services commonly requiring AIM Specialty Health review often include high-cost asthma biologics (such as Dupixent or Nucala), home oxygen, BiPAP/CPAP equipment, and advanced pulmonary function testing. Certain antifibrotic therapies for conditions like Idiopathic Pulmonary Fibrosis may also fall under their purview.

How does Klivira handle the detailed documentation requirements for asthma biologics?

Klivira automates the collection and submission of critical documentation for asthma biologics, including eosinophil counts, confirmation of prior controller therapy at maximum dose, and exacerbation history. Our system is configured with logic informed by clinical guidelines such as GINA, GOLD, and ATS to ensure all necessary criteria are met.

Can Klivira integrate with our existing EMR to pull pulmonology patient data for PAs?

Yes, Klivira is designed for seamless integration with major EMR systems. This allows our platform to automatically extract relevant clinical data, such as diagnostic results, medication history, and physician notes, directly from the patient chart to populate prior authorization requests for submission to AIM Specialty Health and other payers.

What are common reasons for pulmonology prior authorization denials when dealing with specialty benefit managers?

Common denial reasons in pulmonology, particularly with specialty benefit managers, include failure to meet step-therapy requirements for asthma biologics, eosinophil-count thresholds not being met for IL-5-targeting biologics, or insufficient evidence of conservative therapy for conditions like IPF. Klivira helps proactively address these issues.

How does Klivira help improve turnaround times for pulmonology PAs submitted to AIM Specialty Health?

Klivira improves turnaround times by automating data extraction, ensuring complete and accurate submission of documentation aligned with payer and clinical guidelines, and facilitating electronic submission where available. This reduces manual processing delays and the need for resubmissions due to incomplete information.